OncoImmunology
Volume 10, 2021 - Issue 1
Open access
2,580
Views
18
CrossRef citations to date
0
Altmetric
Original Research
Cisplatin inhibits frequency and suppressive activity of monocytic myeloid-derived suppressor cells in cancer patients
Glenn F. Van Wigcherena Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboudumc, Nijmegen, The Netherlands;b Oncode Institute, Utrecht, The NetherlandsView further author information
, Nienke De Haasa Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboudumc, Nijmegen, The NetherlandsView further author information
, Tom A. Muldera Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboudumc, Nijmegen, The Netherlands;c Department of Oncology-Pathology, Karolinska Institutet, Stockholm, SwedenView further author information
, Sophie K. Horrevortsa Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboudumc, Nijmegen, The NetherlandsView further author information
, Martine Bloemendala Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboudumc, Nijmegen, The Netherlands;d Department of Medical Oncology, Radboudumc, Nijmegen, The NetherlandsView further author information
, Simone Hins-Debreea Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboudumc, Nijmegen, The NetherlandsView further author information
, Yumeng Maoc Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden;e Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, SwedenView further author information
, Rolf Kiesslingc Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden
https://orcid.org/0000-0003-0663-5763View further author information
Carla M.L. van Herpend Department of Medical Oncology, Radboudumc, Nijmegen, The NetherlandsView further author information
, Georgina Flórez-Graua Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboudumc, Nijmegen, The NetherlandsView further author information
, Stanleyson V. Hatoa Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboudumc, Nijmegen, The NetherlandsView further author information
& I. Jolanda M. De Vriesa Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboudumc, Nijmegen, The NetherlandsCorrespondence[email protected]
View further author information
show allView further author information
Article: 1935557
|
Received 01 Mar 2021, Accepted 21 May 2021, Published online: 27 Jun 2021
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.